RSNA 2003 Scientific Papers > External Beam Radiotherapy as Treatment for Primary ...
  Scientific Papers
  SESSION: Radiation Oncology and Radiobiology (Genitourinary Cancer II)

External Beam Radiotherapy as Treatment for Primary Prostate Cancer in Very Elderly Patients

  DATE: Thursday, December 04 2003
  START TIME: 10:40 AM
  END TIME: 10:47 AM
  LOCATION: Room S403B
  CODE: Q15-1328

Melvin Deutsch MD
Pittsburgh , PA
Diane Heaton MD
Maury Rosenstein MD

Prostate neoplasms, therapeutic radiology

Purpose: This is a retrospective review to determine tolerance and outcome of external beam radiotherapy for treatment of primary carcinoma of the prostate in men over age 80 years.

Methods and Materials: Thirty-three patients, all at least 80 years old, were treated with external beam radiotherapy for primary carcinoma of the prostate. The pre-radiotherapy PSA varied from 6.6 to 91 (median 15.6). Only six patients had a pre-therapy PSA level below 10. In eleven patients, pathology revealed adenocarcinoma, Gleason grade 8 or above. Five patients had a Gleason grade 7 adenocarcinoma, thirteen had Gleason grade 6 adenocarcinoma, and in four the Gleason grade was unknown. Thirteen patients (39%) received hormonal therapy prior to, and during, radiotherapy. Thirty-two patients received a total radiation dose of 6300-7560 cGy at 180-200 cGy per day. One patient was treated with split course radiotherapy to a dose of 5500 cGy in 22 fractions.

Results: Radiotherapy was well tolerated in all patients and there were no unusual or prolonged interruptions in therapy. Nineteen patients (57.6%) are alive 23-98 months from completion of radiotherapy. Thirteen patients are alive free of disease 23-83 months (median 47 months) and six patients are alive with evidence of progression (elevation in PSA) 44-98 months. Fourteen patients died 2-138 months from completion of radiotherapy. Five died without any evidence of disease at 16-138 months. Four patients definitely died with progressive prostate cancer at 11-27 months and in five patients the status of disease at death, 2-103 months, was unknown. The actuarial overall survival at five years was 60.8%.

Conclusion: Elderly patients, over 80 years of age, with prostate cancer tolerate prostate irradiation well. The overall survival of 60.8% at 5 years suggests that the elderly patient with a good performance status be strongly considered for high dose prostate irradiation.




Questions about this event email: